Gapping up
In reaction to strong earnings/guidance: LIVE +15.4%, CSIQ +9.9%, (expects Q4 results to exceed prior guidance, suspends at-the-market common share sale program due to market conditions) STB +6.6%, QSR +6.2%, CRNT +5.5%,HRL +4%, BBW +2.6%, ORAN +2.4%, PTN +2%, BIOD +1.9%, TTS +1.8%, TLRD+1.5%, YNDX +0.9%
M&A news: ADT +51.7% (agrees to be acquired by Apollo Global Management (APO) for $42.00/share in cash; deal includes 'go-shop' period),FCX +8.5% (to divest 13% stake in Morenci Mine for $1.0 bln in cash)
Select oil/gas related names showing strength: BTE +10.5%, SDRL +7.8%,WLL +4.4%, MRO +4.1%, RDS.A +3%, KMI +2.8%, XOM +1.7%, TOT +1.5%, .
Other news: RMTI +12.2% (enters into exclusive license & manufacturing agreement with Wanbang Biopharmaceutical to commercialize Triferic in China), GRPN +10.7% (Alibaba (BABA) files 13F showing 32,972,000 share position in Groupon (GRPN)), EYES +9% (announces publication of 'positive' results in 3-Year FLORA study of the Argus II ), JKS +8.1% (in symp with CSIQ guidance), VIPS +7.8% (Shanghai +3% overnight), MOMO +6.9% (still checking), SUNE +5.7% (in symp with CSIQ guidance), JD +5.4% (Shanghai +3% overnight), TSLA +4.6% (still checking, may be up with futures this morning), BABA +3.2% (Alibaba (BABA) files 13F showing 32,972,000 share position in Groupon (GRPN)), BIDU +3% (Shanghai +3% overnight), SKX+2.6% (provides preliminary ruling in adidas (ADDYY) lawsuit; no disruption to Skechers business), INCY +2.3% (granted Orphan Designation by the FDA for epacadostat for the treatment of stage IIB-IV melanoma)
Analyst comments: DG +2.5% (upgraded to Overweight at Morgan Stanley),WD +4.5% (upgraded to Overweight from Equal-Weight at Morgan Stanley),BMRN +3.5% (upgraded to Buy from Hold at Stifel), LPLA +3.3% (upgraded to Outperform from Neutral at Credit Suisse), MS +3% (upgraded to Overweight from Neutral at JP Morgan), TTM +2.6% (upgraded to Neutral from Sell at Goldman), PANW +2.4% (upgraded to Buy at DA Davidson), CYS +1.9% (upgraded to Mkt Outperform from Mkt Perform at JMP Securities), GS +1.8% (upgraded to Overweight from Underweight at JP Morgan), MTCH +1.8% (upgraded to Neutral at BTIG), VRX +1.5% (initiated with a Buy at Rodman & Renshaw), PG +1.2% (upgraded to Buy from Neutral at Sterne Agee CRT)
In reaction to strong earnings/guidance: LIVE +15.4%, CSIQ +9.9%, (expects Q4 results to exceed prior guidance, suspends at-the-market common share sale program due to market conditions) STB +6.6%, QSR +6.2%, CRNT +5.5%,HRL +4%, BBW +2.6%, ORAN +2.4%, PTN +2%, BIOD +1.9%, TTS +1.8%, TLRD+1.5%, YNDX +0.9%
M&A news: ADT +51.7% (agrees to be acquired by Apollo Global Management (APO) for $42.00/share in cash; deal includes 'go-shop' period),FCX +8.5% (to divest 13% stake in Morenci Mine for $1.0 bln in cash)
Select oil/gas related names showing strength: BTE +10.5%, SDRL +7.8%,WLL +4.4%, MRO +4.1%, RDS.A +3%, KMI +2.8%, XOM +1.7%, TOT +1.5%, .
Other news: RMTI +12.2% (enters into exclusive license & manufacturing agreement with Wanbang Biopharmaceutical to commercialize Triferic in China), GRPN +10.7% (Alibaba (BABA) files 13F showing 32,972,000 share position in Groupon (GRPN)), EYES +9% (announces publication of 'positive' results in 3-Year FLORA study of the Argus II ), JKS +8.1% (in symp with CSIQ guidance), VIPS +7.8% (Shanghai +3% overnight), MOMO +6.9% (still checking), SUNE +5.7% (in symp with CSIQ guidance), JD +5.4% (Shanghai +3% overnight), TSLA +4.6% (still checking, may be up with futures this morning), BABA +3.2% (Alibaba (BABA) files 13F showing 32,972,000 share position in Groupon (GRPN)), BIDU +3% (Shanghai +3% overnight), SKX+2.6% (provides preliminary ruling in adidas (ADDYY) lawsuit; no disruption to Skechers business), INCY +2.3% (granted Orphan Designation by the FDA for epacadostat for the treatment of stage IIB-IV melanoma)
Analyst comments: DG +2.5% (upgraded to Overweight at Morgan Stanley),WD +4.5% (upgraded to Overweight from Equal-Weight at Morgan Stanley),BMRN +3.5% (upgraded to Buy from Hold at Stifel), LPLA +3.3% (upgraded to Outperform from Neutral at Credit Suisse), MS +3% (upgraded to Overweight from Neutral at JP Morgan), TTM +2.6% (upgraded to Neutral from Sell at Goldman), PANW +2.4% (upgraded to Buy at DA Davidson), CYS +1.9% (upgraded to Mkt Outperform from Mkt Perform at JMP Securities), GS +1.8% (upgraded to Overweight from Underweight at JP Morgan), MTCH +1.8% (upgraded to Neutral at BTIG), VRX +1.5% (initiated with a Buy at Rodman & Renshaw), PG +1.2% (upgraded to Buy from Neutral at Sterne Agee CRT)